# Daxor Corporation (DXR)

Source: https://www.quantisnow.com/company/DXR
Generated: 2026-11-09T00:12:52.977Z

- Ticker: DXR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Medical/Dental Instruments
- SEC CIK: 0000027367
- Website: daxor.com

## About

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. Daxor Corporation has a cooperative research and development agreement with the Uniformed Services University of the Health Sciences for researching the effectiveness of BVA-100 diagnostic test on quantifying circulatory blood volume in the context of traumatic injury. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

## Latest DXR news and filings

- 2026-10-15 12:00 UTC [Daxor Accelerates Commercial Expansion of Next-Gen Blood Volume Diagnostic Platform at MedAxiom CV Transforum Fall '26](https://www.quantisnow.com/insight/daxor-accelerates-commercial-expansion-of-next-gen-blood-volume-diagnostic-platform-6747267)
- 2026-10-14 12:00 UTC [Daxor Announces Strong Commercial Interest and New Clinical Data at HFSA 2026](https://www.quantisnow.com/insight/daxor-announces-strong-commercial-interest-and-new-clinical-data-at-6745934)
- 2026-10-13 12:00 UTC [Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026](https://www.quantisnow.com/insight/daxor-to-showcase-blood-volume-analysis-platform-at-asn-kidney-6744188)
- 2026-10-09 21:01 UTC [Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation](https://www.quantisnow.com/insight/amendment-sec-form-40-8f-2a-filed-by-daxor-corporation-6743161)
- 2026-10-01 12:00 UTC [Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026](https://www.quantisnow.com/insight/daxor-to-showcase-next-gen-blood-volume-analyzer-and-new-clinical-6731447)
- 2026-09-24 21:17 UTC [Amendment: SEC Form N-CEN/A filed by Daxor Corporation](https://www.quantisnow.com/insight/amendment-sec-form-n-cena-filed-by-daxor-corporation-6725740)
- 2026-09-08 21:40 UTC [Conference Announcement] [Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference](https://www.quantisnow.com/insight/daxor-corporation-to-participate-in-the-10th-annual-lake-street-6708782)
- 2026-09-01 19:26 UTC [SEC Form 4] [Chief Medical Officer Jefferies John was granted 2,451 units of Daxor Common Stock, increasing direct ownership by 10% to 26,008 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-jefferies-john-was-granted-2451-units-of-6701219)
- 2026-09-01 12:00 UTC [Public Offering] [Daxor Corporation CEO and President Michael Feldschuh Delivers 1st Half Corporate Update in Shareholder Letter](https://www.quantisnow.com/insight/daxor-corporation-ceo-and-president-michael-feldschuh-delivers-1st-half-6700568)
- 2026-08-31 21:25 UTC [SEC Form N-CSR filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-n-csr-filed-by-daxor-corporation-6700109)
- 2026-08-31 10:15 UTC [SEC Form N-PX filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-n-px-filed-by-daxor-corporation-6698962)
- 2026-07-30 02:40 UTC [Daxor Broadens Outpatient Footprint with Initiation of ezBVA Lab Diagnostic Services in Kansas](https://www.quantisnow.com/insight/daxor-broadens-outpatient-footprint-with-initiation-of-ezbva-lab-diagnostic-6654525)
- 2026-07-07 12:00 UTC [Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas](https://www.quantisnow.com/insight/daxor-corporation-announces-first-time-exhibition-at-the-14th-annual-dysautonomia-6629479)
- 2026-06-25 21:25 UTC [SEC Form 4] [Chief Financial Officer Michel Robert J was granted 12,000 units of Daxor Common Stock, increasing direct ownership by 57% to 33,050 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-michel-robert-j-was-granted-12000-units-6616334)
- 2026-06-25 21:22 UTC [SEC Form 4] [Chief Executive Officer Feldschuh Michael Richard was granted 30,000 units of Daxor Common Stock, increasing direct ownership by 14% to 243,694 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-executive-officer-feldschuh-michael-richard-was-granted-30000-units-6616318)
- 2026-06-25 21:19 UTC [SEC Form 4] [Chief Scientific Officer Feldschuh Jonathan Adam was granted 25,000 units of Daxor Common Stock, increasing direct ownership by 46% to 78,908 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-feldschuh-jonathan-adam-was-granted-25000-units-6616309)
- 2026-06-25 21:16 UTC [SEC Form 4] [SEC Form 4 filed by Director Goudie Joy S.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-goudie-joy-s-6616283)
- 2026-06-25 21:13 UTC [SEC Form 4] [SEC Form 4 filed by Director Cremisi Henry D.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cremisi-henry-d-6616262)
- 2026-06-25 21:11 UTC [SEC Form 4] [SEC Form 4 filed by Director Feuer Edward](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-feuer-edward-6616255)
- 2026-06-25 21:08 UTC [SEC Form 4] [SEC Form 4 filed by Director Desrosiers Caleb](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-desrosiers-caleb-6616241)
- 2026-06-24 20:10 UTC [SEC Form 8-K] [SEC Form 8-K filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-daxor-corporation-6614191)
- 2026-06-17 21:21 UTC [Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation](https://www.quantisnow.com/insight/amendment-sec-form-40-8f-2a-filed-by-daxor-corporation-6607248)
- 2026-06-03 20:17 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-daxor-corporation-6586955)
- 2026-06-02 12:00 UTC [Daxor Corporation Receives U.S. Patent for Breakthrough Remote Blood Volume Monitor](https://www.quantisnow.com/insight/daxor-corporation-receives-us-patent-for-breakthrough-remote-blood-volume-6583272)
- 2026-06-02 01:48 UTC [SEC Form NT NPORT-P filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-nt-nport-p-filed-by-daxor-corporation-6582952)
- 2026-05-21 19:42 UTC [Amendment: SEC Form 40-8F-2/A filed by Daxor Corporation](https://www.quantisnow.com/insight/amendment-sec-form-40-8f-2a-filed-by-daxor-corporation-6567073)
- 2026-05-06 15:57 UTC [SEC Form 40-17F2 filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-40-17f2-filed-by-daxor-corporation-6534795)
- 2026-04-28 12:00 UTC [Daxor Leverages MedAxiom CV Transforum Spring'26 to Accelerate Commercial Adoption of Blood Volume Analysis](https://www.quantisnow.com/insight/daxor-leverages-medaxiom-cv-transforum-spring26-to-accelerate-commercial-adoption-6517727)
- 2026-04-10 17:54 UTC [SEC Form 4] [SEC Form 4 filed by Feldschuh Michael Richard](https://www.quantisnow.com/insight/sec-form-4-filed-by-feldschuh-michael-richard-6495973)
- 2026-04-08 12:00 UTC [Daxor Expands Customer Footprint with New BVA Program at High-Volume Ohio Cardiology Center](https://www.quantisnow.com/insight/daxor-expands-customer-footprint-with-new-bva-program-at-high-volume-6492187)
- 2026-04-02 17:35 UTC [Amendment: SEC Form N-CEN/A filed by Daxor Corporation](https://www.quantisnow.com/insight/amendment-sec-form-n-cena-filed-by-daxor-corporation-6483973)
- 2026-03-31 22:28 UTC [SEC Form 4] [SEC Form 4 filed by Michel Robert J](https://www.quantisnow.com/insight/sec-form-4-filed-by-michel-robert-j-6480170)
- 2026-03-31 19:39 UTC [SEC Form 40-17F2 filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-40-17f2-filed-by-daxor-corporation-6478810)
- 2026-03-26 12:00 UTC [Daxor's Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026](https://www.quantisnow.com/insight/daxors-blood-volume-analysis-metric-validated-as-uniquely-accurate-versus-6469979)
- 2026-03-24 21:58 UTC [SEC Form 4] [SEC Form 4 filed by Jefferies John](https://www.quantisnow.com/insight/sec-form-4-filed-by-jefferies-john-6467668)
- 2026-03-17 12:00 UTC [Daxor Corporation to Showcase Next-Generation Portable Blood Volume Analyzer at ACC.26; Highlighting Clinical Outcomes and Reduced Readmissions](https://www.quantisnow.com/insight/daxor-corporation-to-showcase-next-generation-portable-blood-volume-analyzer-at-6451209)
- 2026-03-16 21:24 UTC [SEC Form N-CEN filed by Daxor Corporation](https://www.quantisnow.com/insight/sec-form-n-cen-filed-by-daxor-corporation-6450255)
- 2026-03-10 12:00 UTC [Daxor to Debut New Rapid, Portable Blood Volume Analyzer at SCCM 2026 Critical Care Congress](https://www.quantisnow.com/insight/daxor-to-debut-new-rapid-portable-blood-volume-analyzer-at-6438682)
- 2026-03-09 12:00 UTC [Conference Announcement] [Daxor Corporation to Participate in the iAccess Virtual Alpha Best Ideas Spring Investment Conference 2026](https://www.quantisnow.com/insight/daxor-corporation-to-participate-in-the-iaccess-virtual-alpha-best-6436276)
- 2026-03-03 13:30 UTC [Public Offering] [Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders](https://www.quantisnow.com/insight/daxor-corporation-ceo-and-president-michael-feldschuh-provides-corporate-update-6424035)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/DXR
- Earnings history: https://www.quantisnow.com/earnings/DXR
- Dividend history: https://www.quantisnow.com/dividends/DXR
- Insider transactions: https://www.quantisnow.com/insiders/DXR
- Options chain: https://www.quantisnow.com/options/DXR
- SEC 8-K filings only: https://www.quantisnow.com/company/DXR/8-k
- RSS and alerts for DXR: https://www.quantisnow.com/docs/rss-feeds.md